{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T07:53:49Z","timestamp":1787730829173,"version":"build-2784847793"},"reference-count":51,"publisher":"MDPI AG","issue":"16","license":[{"start":{"date-parts":[[2022,8,12]],"date-time":"2022-08-12T00:00:00Z","timestamp":1660262400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Institutes of Health\/National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA205146"],"award-info":[{"award-number":["R01CA205146"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Objectives: We developed and validated a disease-specific tool for perioperative patient-reported outcomes assessment for bladder cancer (BLC) patients undergoing radical cystectomy, The MD Anderson Symptom Inventory (the MDASI-PeriOp-BLC). Methods: Patients who underwent radical cystectomy were recruited. We used qualitative interviews and experts\u2019 input to generate disease\/treatment-specific items of the MDASI-PeriOp-BLC module; conducted item reduction; examined the psychometric properties of the resultant items for reliability, validity, and clinical interpretability; and conducted cognitive debriefing interviews to assess the tool\u2019s performance. Results: A total of 150 BLC patients contributed to psychometric validation. We identified and defined eight BLC-specific module items (blood in urine, leaking urine, frequent urination, urinary urgency, burning with urination, constipation, changes in sexual function, and stomal problems). We included those 8 items in addition to 13 MDASI core symptoms and 6 interference items to form the MDASI-PeriOp-BLC module. Cronbach alphas were 0.89 and 0.90 for the 21 severity items and the 6 interference items, respectively. Test\u2013retest reliability (intra-class correlation) was 0.92 for the 21 severity items. The MDASI-PeriOp-BLC module significantly differentiated the patients by performance status (p &lt; 0.0001). Conclusions: The MDASI-PeriOp-BLC is a valid, reliable, and concise tool for monitoring symptom burden during perioperative care in BLC patients undergoing radical cystectomy.<\/jats:p>","DOI":"10.3390\/cancers14163896","type":"journal-article","created":{"date-parts":[[2022,8,14]],"date-time":"2022-08-14T21:09:06Z","timestamp":1660511346000},"page":"3896","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Validation and Application of MD Anderson Symptom Inventory Module for Patients with Bladder Cancer in the Perioperative Setting"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1626-2657","authenticated-orcid":false,"given":"Mona","family":"Kamal","sequence":"first","affiliation":[{"name":"Department of Symptom Research, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1450, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neema","family":"Navai","sequence":"additional","affiliation":[{"name":"Department of Urology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1450, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4532-7763","authenticated-orcid":false,"given":"Kelly K.","family":"Bree","sequence":"additional","affiliation":[{"name":"Department of Urology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1450, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2788-657X","authenticated-orcid":false,"given":"Loretta A.","family":"Williams","sequence":"additional","affiliation":[{"name":"Department of Symptom Research, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1450, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles S.","family":"Cleeland","sequence":"additional","affiliation":[{"name":"Department of Symptom Research, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1450, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7578-5397","authenticated-orcid":false,"given":"Shu-En","family":"Shen","sequence":"additional","affiliation":[{"name":"Department of Symptom Research, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1450, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin Shelley","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Symptom Research, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1450, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,8,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","first-page":"1931","article-title":"Planned preoperative radiation therapy in muscle invasive bladder cancer; results of a meta-analysis","volume":"18","author":"Huncharek","year":"1998","journal-title":"Anticancer Res."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/0360-3016(92)91060-Z","article-title":"Combined pre- and postoperative adjuvant radiation therapy for bladder cancer\u2014A ten year experience","volume":"24","author":"Reisinger","year":"1992","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_4","unstructured":"NCCN (2020, November 15). NCCN Clinical Practice Guidelines in Oncology-Bladder Cancer, Version 3.2019. Available online: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/bladder.pdf."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S0022-5347(01)65047-X","article-title":"Treatment of advanced bladder cancer with combined preoperative irradiation and radical cystectomy versus radical cystectomy alone: A phase III intergroup study","volume":"157","author":"Smith","year":"1997","journal-title":"J. Urol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1200\/JCO.1999.17.8.2546","article-title":"Outcome of postchemotherapy surgery after treatment with methotrexate, vinblastine, doxorubicin, and cisplatin in patients with unresectable or metastatic transitional cell carcinoma","volume":"17","author":"Dodd","year":"1999","journal-title":"J. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1056\/NEJMoa022148","article-title":"Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer","volume":"349","author":"Grossman","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Vashistha, V., Quinn, D.I., Dorff, T.B., and Daneshmand, S. (2014). Current and recent clinical trials for perioperative systemic therapy for muscle invasive bladder cancer: A systematic review. BMC Cancer, 14.","DOI":"10.1186\/1471-2407-14-966"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1016\/j.jsxm.2020.06.015","article-title":"Radical Cystectomy and Perioperative Sexual Function: A Cross-Sectional Analysis","volume":"17","author":"Westerman","year":"2020","journal-title":"J. Sex. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1007\/s00345-016-1950-z","article-title":"90-Day complication rate in patients undergoing radical cystectomy with enhanced recovery protocol: A prospective cohort study","volume":"35","author":"Djaladat","year":"2017","journal-title":"World J. Urol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.eururo.2008.07.031","article-title":"Defining early morbidity of radical cystectomy for patients with bladder cancer using a standardized reporting methodology","volume":"55","author":"Shabsigh","year":"2009","journal-title":"Eur. Urol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/j.eururo.2012.06.007","article-title":"Standardized analysis of frequency and severity of complications after robot-assisted radical cystectomy","volume":"62","author":"Yuh","year":"2012","journal-title":"Eur. Urol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/j.1464-410X.1992.tb16140.x","article-title":"Male and Female Sexual Function and Activity Following Ileal Conduit Urinary Diversion","volume":"72","author":"Nyman","year":"1993","journal-title":"Br. J. Urol."},{"key":"ref_14","first-page":"115","article-title":"Quality of life in patients with advanced bladder cancer. A randomized study comparing cystectomy and irradiation--the Danish Bladder Cancer Study Group (DAVECA protocol 8201)","volume":"125","author":"Mommsen","year":"1989","journal-title":"Scand. J. Urol. Nephrol. Suppl."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3109\/00365598709180301","article-title":"Life with an Ileal Conduit in Cystectomized Bladder Cancer Patients: Expectations and Experience","volume":"21","author":"Reitan","year":"1987","journal-title":"Scand. J. Urol. Nephrol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1097\/01.ju.0000093721.23249.c3","article-title":"Organ Conservation in Invasive Bladder Cancer by Transurethral Resection, Chemotherapy and Radiation: Results of a Urodynamic and Quality of Life Study on Long-term Survivors","volume":"170","author":"Zietman","year":"2003","journal-title":"J. Urol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1002\/(SICI)1097-0142(19960901)78:5<1089::AID-CNCR20>3.0.CO;2-Y","article-title":"Assessment of quality of life after cystectomy or conservative therapy for patients with infiltrating bladder carcinoma: A survey by a self-administered questionnaire","volume":"78","author":"Caffo","year":"1996","journal-title":"Cancer"},{"key":"ref_18","unstructured":"Administration UFaD (2020, November 15). Guidance for Industry. Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims, Available online: https:\/\/www.fda.gov\/media\/77832\/download."},{"key":"ref_19","unstructured":"Agency, E.M. (2020, November 15). Appendix 2 to the Guideline on the Evaluation of Anticancer Medicinal Products in Man. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/other\/appendix-2-guideline-evaluation-anticancer-medicinal-products-man_en.pdf."},{"key":"ref_20","unstructured":"FDA (2020, November 15). Core Patient-Reported Outcomes in Cancer Clinical Trials-Guidance for Industry, Available online: https:\/\/www.fda.gov\/media\/149994\/download."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/00005392-199907000-00019","article-title":"Quality of life after radical cystectomy for bladder cancer in patients with an ileal conduit, or cutaneous or urethral kock pouch","volume":"162","author":"Hart","year":"1999","journal-title":"J. Urol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/S0022-5347(17)45192-5","article-title":"Sexual Rehabilitation and Male Radical Cystectomy","volume":"136","author":"Schover","year":"1986","journal-title":"J. Urol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.ejso.2014.05.006","article-title":"Health related quality of life (HRQoL) after cystectomy: Comparison between orthotopic neobladder and ileal conduit diversion","volume":"41","author":"Ali","year":"2015","journal-title":"Eur. J. Surg. Oncol. (EJSO)"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1007\/s00345-019-02692-z","article-title":"Propensity-matched analysis of patient-reported outcomes for neoadjuvant chemotherapy prior to radical cystectomy","volume":"37","author":"Feuerstein","year":"2019","journal-title":"World J. Urol."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Van Hemelrijck, M., Sparano, F., Josephs, D., Sprangers, M., Cottone, F., and Efficace, F. (2019). Patient-reported outcomes in randomised clinical trials of bladder cancer: An updated systematic review. BMC Urol., 19.","DOI":"10.1186\/s12894-019-0518-9"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s11912-020-0890-3","article-title":"Integration of Patient Reported Outcomes in Drug Development in Genitourinary Cancers","volume":"22","author":"Wong","year":"2020","journal-title":"Curr. Oncol. Rep."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.euros.2021.01.014","article-title":"Development of the First Patient-centred Set of Outcomes for Muscle-invasive and Metastatic Bladder Cancer: A Multicentre Initiative","volume":"26","author":"Reesink","year":"2021","journal-title":"Eur. Urol. Open Sci."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2986","DOI":"10.21037\/tau.2020.03.44","article-title":"Enhanced recovery after surgery of patients undergoing radical cystectomy for bladder cancer","volume":"9","author":"Sung","year":"2020","journal-title":"Transl. Androl. Urol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.jpainsymman.2016.07.005","article-title":"Patient-Reported Symptom Interference as a Measure of Postsurgery Functional Recovery in Lung Cancer","volume":"52","author":"Shi","year":"2016","journal-title":"J. Pain Symptom Manag."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1200\/JCO.2010.29.8315","article-title":"Automated symptom alerts reduce postoperative symptom severity after cancer surgery: A randomized controlled clinical trial","volume":"29","author":"Cleeland","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.jtcvs.2015.05.057","article-title":"Symptom recovery after thoracic surgery: Measuring patient-reported outcomes with the MD Anderson Symptom Inventory","volume":"150","author":"Fagundes","year":"2015","journal-title":"J. Thorac Cardiovasc. Surg."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1002\/bjs.8990","article-title":"Contemporary perioperative care strategies","volume":"100","author":"Adamina","year":"2013","journal-title":"Br. J. Surg."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.surg.2011.07.045","article-title":"Impact of preoperative change in physical function on postoperative recovery: Argument supporting prehabilitation for colorectal surgery","volume":"150","author":"Mayo","year":"2011","journal-title":"Surgery"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.eururo.2021.02.023","article-title":"Seeing the Unseen: Uncovering Patient-reported Outcomes in Bladder Cancer","volume":"79","author":"Smith","year":"2021","journal-title":"Eur. Urol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e13157","DOI":"10.1111\/and.13157","article-title":"Psychological impact of different primary treatments for prostate cancer: A critical analysis","volume":"51","author":"Maggi","year":"2019","journal-title":"Andrologia"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1177\/1553350618764218","article-title":"Patient-Reported Outcomes Are Associated With Enhanced Recovery Status in Patients With Bladder Cancer Undergoing Radical Cystectomy","volume":"25","author":"Kukreja","year":"2018","journal-title":"Surg. Innov."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21551","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Cancer J. Clin."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1002\/1097-0142(20001001)89:7<1634::AID-CNCR29>3.0.CO;2-V","article-title":"Assessing symptom distress in cancer patients","volume":"89","author":"Cleeland","year":"2000","journal-title":"Cancer."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the Eastern Cooperative Oncology Group","volume":"5","author":"Oken","year":"1982","journal-title":"Am. J. Clin. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J. Chronic Dis."},{"key":"ref_41","unstructured":"EORTC (2020, November 15). EORTC-BLM30. Available online: https:\/\/qol.eortc.org\/questionnaire\/qlq-blm30\/."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1200\/JCO.2010.33.4631","article-title":"Relationship Between Deficits in Overall Quality of Life and Non\u2013Small-Cell Lung Cancer Survival","volume":"30","author":"Sloan","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_43","unstructured":"Degboe, A., Ivanescu, C., Rohay, J.M., Turner, R.R., and Cella, D. (2020, November 15). Functional Assessment of Cancer Therapy\u2014Bladder cancer (FACT-Bl). Available online: https:\/\/eprovide.mapi-trust.org\/instruments\/functional-assessment-of-cancer-therapy-bladder-cancer."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.clnu.2013.09.014","article-title":"Guidelines for perioperative care after radical cystectomy for bladder cancer: Enhanced Recovery After Surgery (ERAS\u00ae) society recommendations","volume":"32","author":"Cerantola","year":"2013","journal-title":"Clin. Nutr."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1586\/14737140.4.6.1017","article-title":"Management of muscle-invasive bladder cancer in the elderly","volume":"4","author":"Basso","year":"2004","journal-title":"Expert Rev. Anticancer"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.eururo.2012.11.015","article-title":"Use of Potentially Curative Therapies for Muscle-invasive Bladder Cancer in the United States: Results from the National Cancer Data Base","volume":"63","author":"Gray","year":"2013","journal-title":"Eur. Urol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S0167-8140(01)00455-8","article-title":"Distressful symptoms after radical radiotherapy for urinary bladder cancer","volume":"62","author":"Henningsohn","year":"2002","journal-title":"Radiother. Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1097\/01.ju.0000092830.03247.ef","article-title":"Health Related Quality of Life in Patients Treated With Radical Cystectomy and Urinary Diversion for Urothelial Carcinoma of the Bladder: Development and Validation of a New Disease Specific Questionnaire","volume":"170","author":"Cookson","year":"2003","journal-title":"J. Urol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1016\/j.juro.2010.01.013","article-title":"Development and Validation of the Bladder Cancer Index: A Comprehensive, Disease Specific Measure of Health Related Quality of Life in Patients With Localized Bladder Cancer","volume":"183","author":"Gilbert","year":"2010","journal-title":"J. Urol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1023\/A:1008890401133","article-title":"The European Organization for Research and Treatment of Cancer Approach to Developing Questionnaire Modules: An Update and Overview","volume":"7","author":"Sprangers","year":"1998","journal-title":"Qual. Life Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"4189","DOI":"10.1007\/s00520-019-04709-0","article-title":"Validity and performance of the Functional Assessment of Cancer Therapy-Bladder (FACT-Bl) among advanced urothelial cancer patients","volume":"27","author":"Degboe","year":"2019","journal-title":"Supportive Care Cancer"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/16\/3896\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:07:37Z","timestamp":1760141257000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/16\/3896"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,12]]},"references-count":51,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2022,8]]}},"alternative-id":["cancers14163896"],"URL":"https:\/\/doi.org\/10.3390\/cancers14163896","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,12]]}}}